Abstract
Azole-therapy failure in HIV-infected patients with mucosal candidose; risk-factors and in-vitro susceptibility. Objective. To study risk-factors for azole-therapy failure in HIV-infected patients with mucosal candidose. Design. Retrospective, descriptive study. Setting. Utrecht University Hospital. Method. Clinical and microbiological data of 40 HIV-infected patients with oral or esophageal candidose were analyzed. In-vitro susceptibility of Candida isolates was determined by the standard method (NCCLS M27) and a commercial method (Etest). Results. During the first candidose episode during the study 29 out of 40 patients responded to azole therapy. Esophageal candidose and previous intensive azole-therapy formed risk-factors for therapy failure. Increased failure for isolates with decreased in-vitro susceptibility could not be demonstrated. Isolation of C. non-albicans isolates did not influence therapy response. Conclusion. Therapy failure is more prevalent in patients with esophageal location of infection and after intensive, maintenance or recent azole therapy. Isolates with decreased susceptibility showed no correlation to therapy failure.
| Translated title of the contribution | Azole-therapy failure in HIV-infected patients with mucosal candidose; risk-factors and in-vitro susceptibility |
|---|---|
| Original language | Dutch |
| Pages (from-to) | 14-20 |
| Number of pages | 7 |
| Journal | Nederlands tijdschrift voor medische microbiologie |
| Volume | 7 |
| Issue number | 1 |
| Publication status | Published - 1999 |